Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Studiehistorikk - Phase1
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
PDF) New clinical trial designs in the era of Precision Medicine
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Phase 2 study of pembrolizumab in patients with advanced rare cancers | Journal for ImmunoTherapy of Cancer
Table of Contents page: Annals of Oncology
Life | Free Full-Text | Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
New clinical trial designs in the era of precision medicine
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
PDF) New clinical trial designs in the era of Precision Medicine
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
Is Debiopharm Group late reporting EU clinical trials?
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Targeting FGFR inhibition in cholangiocarcinoma - ScienceDirect
2019 ASCO Annual Meeting Proceedings Immuno-Oncology Abstracts | Journal of Clinical Oncology
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
